Clinical Trials Browser

Phase 2 × Completed × Enteropathy-Associated T-Cell Lymphoma × Clear all

NCT02588651 2025-11-21

A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)

Immunoblastic Lymphadenopathy, Leukemia, Lymphoma, Lymphoma, T-Cell, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Enteropathy-Associated T-Cell Lymphoma

NCT03217643 2024-06-20

EATL-001

Phase 2 Completed

14 enrolled

Lymphoid

Enteropathy-Associated T-Cell Lymphoma

NCT00901147 2014-06-27

Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma

Phase 2 Completed

25 enrolled

Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Extranodal NK-T-Cell, Enteropathy-Associated T-Cell Lymphoma